Latest News
- June 05, 2025Join CBCC at CPHI China 2025
- June 02, 2025Successfully completed a Phase 1a study for a US-based Innovator Biotech Company!
- May 26, 2025ANDA application for Paclitaxel Injection (Albumin bound) supported by CBCC has received Marketing Authorization from the USFDA
- May 20, 2025We’re Exhibiting at BIO 2025! Visit our booth #3480
- May 15, 2025Join CBCC Global Research at #ASCO25
January 07, 2024
We welcome Dr David Bearss to our strategic advisory board
We are pleased to announce the induction of David Bearss Ph.D. to our strategic advisory board as a key advisor for clinical trials.
Dr. David Bearss is the CEO of Halia Therapeutics, Inc. He is an experienced entrepreneur and drug developer with 20 plus years of experience in academic and industry settings.
We are confident that Dr. Bearss’ comprehensive understanding of the drug development life cycle and technical expertise in all aspects of patient care will add immeasurable value to our Customer’s Clinical Development Plans.
CBCC Global Research: CHANGING LIVES THROUGH HOPE AND INNOVATION
